Recent advances in nanotechnology have enabled ECM-specific interventions that selectively bind to matrix molecules such as collagen and fibronectin, delivering antifibrotic agents or matrix-degrading enzymes directly to tumor sites [[124], [125], [126]]. This evidence concerns the gene FN1 and neoplasm.